Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies

COMMENTED

Cardiovascular Risk and Diseases

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW

doi: 10.1016/S2213-8587(25)00165-2

COMMENTED

Cardiovascular Risk and Diseases

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

Lancet Diabetes Endocrinol

Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D

doi: 10.1016/S2213-8587(24)00396-6

COMMENTED

Cardiovascular Risk and Diseases

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

N Engl J Med

McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group

doi: 10.1056/NEJMoa2501006

Heart, Artery and Coronary Diseases

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Am Heart J

Haff N, Horn DM, Bhatkhande G, Sung M, Colling C, Wood W, Robertson T, Gaposchkin D, Simmons L, Yang J, Yeh J, Crum KL, Hanken KE, Lauffenburger JC, Choudhry NK

doi: 10.1016/j.ahj.2025.02.007

Cardiovascular Risk and Diseases

Sex differences in 10-year cardiovascular risk of patients with type 2 diabetes mellitus and subclinical hypothyroidism: a cross-sectional study

Front Endocrinol (Lausanne)

Zhao X, He K, Li J, Zhou L, Liu L, Lu X, Jiang Y

doi: 10.3389/fendo.2025.1635444

Myocardial Infarction

Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries

Circ Cardiovasc Qual Outcomes

Mentias A, Keshvani N, Desai MY, Kapadia S, Ziada KM, McCarthy CP, Hall HM, Park K, Kumbhani DJ, Lincoff AM, Januzzi JL Jr, Pandey A

doi: 10.1161/CIRCOUTCOMES.125.012136

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Cardiovascular Risk and Diseases

Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

Diabetes Obes Metab

Nanna MG, Doan QV, Fabricatore A, Faurby M, Henry AD, Houshmand-Oeregaard AS, Levine A, Navar AM, Scassellati Sforzolini T, Toliver JC

doi: 10.1111/dom.16370

Cardiovascular Risk and Diseases

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study

Diabetes Obes Metab

Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J

doi: 10.1111/dom.70214

Related content

Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data

Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial

Sex differences in 10-year cardiovascular risk of patients with type 2 diabetes mellitus and subclinical hypothyroidism: a cross-sectional study

Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial

Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study